Skip to main content

Table 1 Patients’ characteristics

From: Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

  Patients Controls
Total VMP VMPT
n 124 53 71 54
Age 71 (56–85) 71 (60–85) 71 (56–85) 69 (54–88)
Sex (M/F) 58/66 24/29 34/37 24/30
Type of MM NA
 IgG (%) 71 (57.2) 31 (58.5) 46 (64.8)  
 IgA (%) 28 (22.6) 12 (22.6) 14 (19.8)  
 BJ (%) 25 (20.2) 10 (18.9) 11 (15.4)  
Stage (D&S) NA
 IIA (%) 14 (11.3) 5 (9.4) 9 (12.7)  
 IIIA (%) 102 (82.3) 45 (84.9) 57 (80.3)  
 IIIB (%) 8 (6.4) 3 (5.7) 5 (7)  
ISS stage NA
 1 26 8 18  
 2 42 21 21  
 3 21 6 15  
 Missing data 35 18 17  
Cytogenetics NA
 High risk 28 11 17  
 Standard risk 36 16 20  
 Missing data 60 26 34  
Response
 CR (%) 47 (37.9) 14 (26.4) 33 (46.6)  
 VGPR (%) 27 (21.8) 11 (20.8) 16 (22.6) NA
 PR (%) 38 (30.6) 19 (35.8) 19 (26.8)  
 SD (%) 12 (9.7) 9 (17) 3 (4.2)  
Relapse (Y/N) 80/44 39/14 41/30 NA
Death (Y/N) 54/70 22/31 32/39 NA
  1. NA not applicable